136 results about "Taxifolin" patented technology

A probiotic composition essentially comprises 15 to 20 wt % of milk powder, 25 to 30 wt % of corn starch, 8 to 15 wt % of modified starch (capsul), 10 to 15 wt % of ethylcellulose, 5 to 15 wt % of bacterial broth, and 10 to 15 wt % of talc. The probiotic composition is microencapsulated to form a plurality of microencapsule coated with an acid-resistant enteric coating for improving the enteric acid-resistance, the probiotic survival rate, the antimicrobial property, the stability, the moisture-proof property, and the mobility of the probiotic composition preventing from coagulation in a moist environment and for being used as an additive applied to livestock feed.

The invention belongs to the technical field of pesticides and in particular relates to a traditional Chinese medicine type crop seed-dressing agent and a using method and an application thereof. The Chinese medicine type crop seed-dressing agent is mainly prepared from the following ingredients: 70-75% of traditional Chinese medicine powder mixture, 15-25% of sulfur powder, and 2-5% of kaolin or talcum powder, wherein the traditional Chinese medicine powder mixture is prepared from the following ingredients in part by weight: 20-25 parts of crushed garlic bulblet, 20-25 parts of crushed Houttuynia cordata, 12-20 parts of crushed purslane, 4-5 parts of crushed folium artemisiae argyi, 4-5 parts of crushed ginkgo leaf, and 4-5 parts of crushed sweet wormwood. The seed-dressing agent is used for preventing and killing pathogenic bacteria and fungi in crop seeds, soil and water body, is used for seed-dressing and can be sown in the same day, has an effective rate up to more than 90%, is non-toxic, has good water permeability and gas permeability, does not affect the life and the respiration of the seeds, and can reduce and avoid damage caused by rats, birds trouble and soil insect damage.

The present invention is a hair treatment agent comprising a combination of dihydroquercetin and/or a dihydroquercetin derivative with at least one amino acid. A preferred hair treatment agent comprises a combination of dihydroquercetin (taxifolin) with a six-amino acid mixture consisting of taurine, proline, valine, arginine, lysine, and glycine. The inventive hair treatment agent positively influences the natural pigmentation process of skin and skin appendages, such as for example, stimulating melanogenesis and pigmentation of hair, preventing and reducing the graying of hair, and repigmenting gray hair.

The invention provides a Ca/Zn compound heat stabilizer, which is prepared by synthesizing a Ca/Zn main stabilizer by using higher fatty acid, ZnO and Ca(OH)2, matching with hydrotalcite and similar hydrotalcite substances and adding proper amount of auxiliary stabilizer, antioxidant, ultraviolet absorber, lubricant and talcum powder, wherein the Ca/Zn main stabilizer accounts for 40-60 percent, the hydrotalcite and similar hydrotalcite substances account for 7-20 percent, the auxiliary stabilizer accounts for 8-30 percent, the antioxidant accounts for 0.1-2.5 percent, the ultraviolet absorber accounts for 0.1-1.5 percent, the lubricant accounts for 1-15 percent and the calcium powder accounts for 1-15 percent, and the percent refers to weight percent. In the stabilizer, the hydrotalcite and similar hydrotalcite substances are mixed according to a certain proportion, thereby the heat resistance is very good, and the color changing time of Congo red can reach more than 80 min. The stabilizer can effectively restrain the degradation of polrvinyl chloride (PVC) material, which is caused by physical actions during forming and processing, such as heating, rubbing, cutting and the like, and exterior conditions in using process, such as light, heat, oxygen and the like, avoid the degradation or aging of the product and prevent the performance reduction of the PVC products. The invention can replace traditional lead salt and organo-tin heat stabilizer with expensive price, can be widely applied to the aspects of PVC processing and forming, and has remarkable social benefits and economic benefits.

The present invention provides a cannabis-based flavonoid pharmaceutical composition including any one or more selected from the group of Apigenin, Cannflavin A, Cannflavin B, Cannflavin C, Chrysoeriol, Cosmosiin, Flavocannabiside, Kaempferol, Luteolin, Myricetin, Orientin, Isoorientin (Homoorientin), Quercetin, (+)-Taxifolin, Vitexin, and Isovitexin, or their synthases, for the prevention and treatment of certain diseases of the CNS system and related disorders.

A topical cosmetic composition for increasing skin whitening or lightening is described. The composition includes a pomegranate extract in an amount effective to reduce melanin composition. The pomegranate extract may be standardized to about 20% punicalagin. The composition may also include an extract from the genus larix, such as Larix sibirica. The larix sibirica may be standardized to 80% taxifolin. A method for using the compositions is described.

The invention discloses a method of preparing a taxifolin monomer from engelhardtia leaves and an application, and the method comprises the following steps: crushing or cutting dried engelhardtia leaves into segments, adding ethanol with a certain concentration, performing extraction, concentrating the obtained extract liquid to paste; adding a buffer with a pH of 3-6, adding a proper amount of enzymes for enzymatic hydrolysis at a certain temperature, performing separation, enrichment, purification, and recrystallization treatment of the enzymatic hydrolysate to obtain a taxifolin monomer with purity of above 99%. The method of the invention is characterized in that enzymatic hydrolysis of the engelhardtia leaf extract is directly performed to obtain the taxifolin monomer with high purity, and the method of the invention has the advantages of strong reaction specificity, high conversion rate, simple and practical process, less pollution, and suitability for large-scale industrial production, and the like. The disadvantages of great destructive effect on aglycone, poor specificity, low conversion rate, high equipment corrosivity, severe pollution, tedious process and the like in the prior art are overcome. The taxifolin monomer prepared in the invention is applicable to the prevention and treatment of fatty liver.

Methods for obtaining a stable solution to enhance bioavailability of flavonoids (e.g. Taxifolin/Dihydromericetine, or Quercetin) include the following steps: -mixing, in predetermined amount, the flavonoid with Citric acid, obtaining a first mixture, grinding the first mixture for 10-15 minutes, mixing the first mixture with a predetermined amount of L-Arginine, obtaining a second mixture, grinding the second mixture for 15 minutes, and either adding water to the second mixture, thereby obtaining the stable solution, or storing the second mixture for further use. Exemplarily, there are disclosed specific weight amounts for each ingredient of the solution.

The invention discloses water soluble medicament sustained-release tablets, which comprise the following components in part by weight: water soluble medicament 1-30, octadecanol 5-70, Eudragite L 100-55 2-50, talcpowder 2-30 and lactose 2-30. The water soluble medicament may be galanthamine hydrobromide, captopril, metoprolol tartaric acid or pseudoephedrine hydrochloride. In the invention, the octadecanol serving as a hydrophobic auxiliary material and the Eudragite L 100-55 sreving as a water soluble polymer auxiliary are adopted, so the release speed of the medicament can be controlled properly. The Eudragite L 100-55 is insoluble in gastric juice, but dissolves in duodenal juice to make high-viscosity sticky liquid, and thus the release and diffusion speed of the medicament can be reduced. The talcpowder which is a hydrophilic matter insoluble in water plays a porogen role in the sustained-release tablets. In the invention, the release speed of the medicament is regulated by regulating the mixing ratio of the medicament to the auxiliary material. Thus, the release speed of an active medicament is controlled.

The present invention relates to loratadine medicine, and is especially oral loratadine disintegrating tablet for treating allergic diseases and its preparation process. The oral loratadine disintegrating tablet consists of loratadine 11 wt%, micro crystal cellulose 56 wt%, mannitol 22 wt%, low substituted hydroxypropyl cellulose 8 wt%, and aspartame 2 wt%, except lubricant comprising magnesium stearate, polyglycol-6000 and talcum. The preparation process includes the pre-treatment of the components, mixing, pelletizing, drying, further mixing with lubricant, and tabletting. The present invention has short disintegrating time and easy taking.

The invention provides a special material for an automobile bumper. The special material is prepared from the following ingredients in parts by mass: 30-50 parts of PPE plastics, 10-30 parts of toughening agent, 0.5-1 part of associating agent, 20-40 parts of filler, 1-4 parts of lubricant, 1-6 parts of antioxidant and 1-8 parts of dispersing aid, wherein the toughening agent is poe (8150); the associating agent is bismaleimide; the filler is talcum powder with the mesh size of 1,250 meshes; the lubricant is pe wax; the antioxidant is an antioxidant 1010; and the dispersing aid is a polyacrylic dispersing agent. The special material for the automobile bumper has the beneficial effects that the bumper material obtained by the formula has higher specific strength, and compared with the original glass-reinforced plastic, the weight is lower and the energy consumption is lowered; the impact absorption capacity is enhanced, and the automobile bumper has the advantages of high rigidity, high heat resistance, flame resistance, relatively high strength, excellent electric properties and the like.

An improved concealer pen is composed of a component A, a component B, a component C, a component D and a component E. The component A is composed of water, butanediol, glycerin, sodium chloride, sodium dehydroacetate, shea butter, potassium sorbate, sodium hyaluronate, methyl methacrylate cross-linked polymer, and an aqueous solution of sodium hyaluronate. The component B is composed of a mixture of cyclohexasiloxane and cyclopentasiloxane, C12-15 alkyl benzoate, aluminum oxide, and a mixture of titanium dioxide and triethoxycaprylylsilane. The component C is composed of ozocerite, hydrogenated coco-glycerides, copernicia cerifera wax and cetyl PEG/PPG-10/1 polydimethylsiloxane. The component D is composed of a mixture of ethylhexylglycerin and phenoxyethanol, glycine betaine and butanediol. The component E is composed of a mixture of polymethylsiloxane and talcum powder, a mixture of hydrogenated macadamia seed oil and macadamia seed oil, and panthenol. The improved concealer pen is refreshing and breathable, has a moisturizing effect, and can better fit skin.

The invention relates to a motherwort and astragalus capsule used for treating prostatic hyperplasia and can effectively solve the treatment problem of benign prostatic hyperplasia. The technical schemes are as follows: the motherwort and astragalus capsule is prepared from motherwort extract, astragalus extract, starch and talcum powder, wherein the weight ratio of the motherwort extract to the astragalus extract is (4-6):(6-4); and the motherwort and astragalus capsule is prepared by crushing the motherwort extract and the astragalus extract, screening with a 100-mesh sieve, mixing uniformly, then adding starch and talcum powder, uniformly mixing, wherein the addition amount of starch and talcum powder is not more than 10% the total weight of the motherwort extract, astragalus extract, starch and talcum powder and the weight ratio of starch to talcum powder is 1:1, granulating and encapsulating. The motherwort and astragalus capsule provided by the invention has the advantages of simple preparation method, proper compatibility, good efficacy, no toxic or side effect and significant treatment effect on benign prostatic hyperplasia, is innovative in the treatment of benign prostatic hyperplasia, and has huge economic and social benefits.

The invention discloses a methane sulfonic acid pradaxa pellet and a preparation method and belongs to the technical field of medicals. The structure of the pellet comprises a pellet core, an isolating layer and a drug-containing layer, wherein the isolating layer is wrapped on the outer layer of the pellet core; the drug-containing layer is wrapped on the outer layer of the isolating layer; glycine and hydroxypropyl methylcellulose are contained in the pellet core; hydroxypropyl methylcellulose phthalic ester and talcum powder are contained in the isolating layer; methane sulfonic acid pradaxa, methyl methacrylate and talcum powder are contained in the drug-containing layer. The surface of the isolating layer of the pellet prepared according to the invention is round and smooth; no so-called satellite particle exists; the completeness of the isolating layer is not influenced, so that the active ingredients and the glycine can be effectively isolated in space and the stability of the active ingredients of the preparation in a storage process can be guaranteed. The methane sulfonic acid pradaxa pellet prepared according to the invention has the effects of preventing and treating cerebral ischemia and systemic embolism diseases.

The invention belongs to the traditional Chinese medicine field and provides a method for preparing taxifolin from fruit of princesplume ladysthumb. The method concretely includes that: dilute alcohol crushing extraction is adopted, extract is subject to centrifugation and then is put on chromatographic column, firstly water is used for washing impurities away, then ethanol is used for eluting, eluent is destained by active carbon, destaining solution is put on chromatographic column again, chloroform-ethanol is used for eluting, reduced pressure concentration, recrystallization and drying are carried out, and clear crystal is obtained. The invention has the characteristics that crushing extraction is adopted, speed is fast, the process is safe, and a lot of time can be saved.

The invention discloses a method for producing compound procaine hydrochloride capsules. According to the method, procaine hydrochloride, glutamic acid and starch are premixed and then smashed and screened, and potassium metbisulphite, talcum powder and benzoic acid are premixed and then smashed and screened; monopotassium phosphate is dissolved in purified water to serve as a bonding agent, then a soft material is made with an efficient wet granulation machine by means of procaine hydrochloride, vitamin B6, inositol, glutamic acid and starch, granulation is conducted with a swing type granulation machine, drying is conducted, and the potassium metbisulphite, the benzoic acid and the talcum powder are added during total blending. By the adoption of the method, the problem of traditional methods that a large amount of irritating odor is generated during production is solved, prepared granules are high in mobility and dissolution rate, filling is smooth, and the manufacturing technique is more stable. Operation is easy, preparation is convenient, cost is low, and the method is suitable for industrial large-scale production.